117 research outputs found
THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells
Chimeric antigen receptor (CAR) T cell costimulation mediated by CD28 and 4-1BB is essential for CAR-T
cell-induced tumor regression. However, CD28 and 4-1BB differentially modulate kinetics, metabolism
and persistence of CAR-T cells, and the mechanisms governing these differences are not fully understood.
We found that LCK recruited into the synapse of CD28-encoding CAR by co-receptors causes antigen-independent
CAR-CD3z phosphorylation and increased antigen-dependent T cell activation. In contrast, the synapse
formed by 4-1BB-encoding CAR recruits the THEMIS-SHP1 phosphatase complex that attenuates
CAR-CD3z phosphorylation. We further demonstrated that the CAR synapse can be engineered to recruit
either LCK to enhance the kinetics of tumor killing of 4-1BB CAR-T cells or SHP1 to tune down cytokine
release of CD28 CAR-T cells
In vitro expansion of CD34+CD38- cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia
advance online publication, August 8, 2014 [Epub ahead of print]ArticleLEUKEMIA. 29(3):606-614 (2015)journal articl
Feasibility of methotrexate discontinuation following tocilizumab and methotrexate combination therapy in patients with long-standing and advanced rheumatoid arthritis: a 3-year observational cohort study
Objectives: Methotrexate (MTX) is associated with extensive side effects, including myelosuppression, interstitial pneumonia, and infection. It is, therefore, critical to establish whether its administration is required after achieving remission with tocilizumab (TCZ) and MTX combination therapy in patients with rheumatoid arthritis (RA). Therefore, the aim of this multicenter, observational, cohort study was to evaluate the feasibility of MTX discontinuation for the safety of these patients. Methods: Patients with RA were administered TCZ, with or without MTX, for 3 years; those who received TCZ+MTX combination therapy were selected. After remission was achieved, MTX was discontinued without flare development in one group (discontinued [DISC] group, n = 33) and continued without flare development in another group (maintain [MAIN] group, n = 37). The clinical efficacy of TCZ+MTX therapy, patient background characteristics, and adverse events were compared between groups. Results: The disease activity score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR) at 3, 6, and 9 months was significantly lower in the DISC group (P < .05, P < .01, and P < .01, respectively). Further, the DAS28-ESR remission rate at 6 and 9 months and Boolean remission rate at 6 months were significantly higher in the DISC group (P < .01 for all). Disease duration was significantly longer in the DISC group (P < .05). Furthermore, the number of patients with stage 4 RA was significantly higher in the DISC group (P < .01). Conclusions: Once remission was achieved, MTX was discontinued in patients who responded favorably to TCZ+MTX therapy, despite the prolonged disease duration and stage progression
Design methodology and optimization strategy for dual-vth scheme using commercially available tools
Design methodology for dual-V TH scheme using commercially available tools is presented and optimization strategy for the dual-V TH scheme is discussed. In order to suppress the power consumption, it is shown that using library cells that have various combinations of V TH’s is not needed. The cell library, which contains logic gates with all high V TH transistors and all low V TH transistors, is sufficient to reduce leakage power. 0.1V is shown to be the optimum value for V TH difference between V TH,HIGH and V TH,LOW in terms of power reduction. 1
- …